| Agent | FDA Approval | Mean Weight Loss (RCT) | Route | |---|---|---|---| | Semaglutide 2.4 mg (Wegovy) | Yes (2021) | 14.9% at 68 weeks (STEP-1, N=1,961) [9] | Subcutaneous weekly | | Tirzepatide 15 mg (Zepbound) | Yes (2023) | 20.9% at 72 weeks (SURMOUNT-1, N=2,539) [11] | Subcutaneous weekly | | AOD-9604 1 mg oral | No | ~2.8 kg at 12 weeks (Phase IIb, N=300 approx.) [1] | Oral (not currently compounded) | The weight-loss magnitude from the single Phase IIb AOD-9604 trial is substantially smaller than what STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) demonstrated in larger, longer trials
Importantly, treatment did not negatively impact markers such as bone mineral density (BMD) or body weight in a manner inconsistent with healthy controls (Fawcett 2010)
It is usually important for people with kidney or internal organ problem
Mental Impairment Low B12 levels can worsen mental function, especially in older adults
Though early research and anecdotal testimonials suggest promise for weight management, its important to acknowledge that AOD-9604 remains an investigational substance requiring further scientific validation
This upstream metabolic shift sets the stage for the other benefits of 5-Amino-1MQ, including improved mitochondrial performance and activation of longevity-associated proteins like sirtuins